Drug companies panic as thirteen 'blockbuster' drugs about to lose patent protection
Jonathan Benson, staff writer
According to data compiled by EvaluatePharma, a pharmaceutical and biotechnology industry analysis group, more than $15 billion worth of drug patents are set to expire in 2011, and another $133 billion worth of drugs in the next six years. One of the biggest blockbuster drugs, Pfizer's $11 billion heart drug Lipitor, is also set to expire late in 2011.
Other patent expirations to occur in 2011 include Eli Lilly's Zyprexa and Johnson & Johnson's Levaquin. And in 2012, Bristol-Myers Squibb's Plavix, AstraZeneca's Seroquel, Merck & Co.'s Singulair, Takeda's Actos, and Amgen's Enbrel, all face patent expirations. To put the patent losses into perspective, more than double the value of drugs are expected to lose their patents in 2012 compared to in 2011.
While some sources are bemoaning these losses as a big hit to the drug industry, which they naively view as the medical saviors of mankind, the patent losses are a big win for the public. Not only do they demonopolize drug industry control over FDA-approved medical treatments, thus reducing costs for patients, but they also stop the industry from endlessly raking in billions of dollars in profits for products that cause millions of serious injuries and deaths every year (http://www.naturalnews.com/024632_d...).
The drug industry is not giving up, though, as it scrambles to concoct new blockbuster drugs to keep the cash cow flowing. But sources say many drug companies are having difficulty coming up with new ones. And they face additional problems from the growing awareness that many natural remedies are superior to drugs because they provide increased benefits and real improvements, without the harmful side effects.
Sources for this story include:
http://www.prnewswire.com/news-rele...
www.naturalnews.com/031234_drug_patents.html
Feb. 7, 2011